BioCentury | Jul 10, 2018
Distillery Therapeutics

Cancer

INDICATION: Liver cancer In vitro , cell culture and mouse studies identified a SALL4-derived peptide inhibitor of the SALL4-RBBP4 interaction that could help treat hepatocellular carcinoma (HCC). Chemical synthesis and in vitro testing of analogs of...
BioCentury | Apr 10, 2018
Distillery Techniques

Drug platforms

...Cas9. The system utilizes an engineered enzyme consisting of standard Cas9 fused to retinoblastoma binding protein 8 (RBBP8; CTIP...
...vs. 1% of harvested embryos, respectively). Next steps include producing recombinant Cas9 fused to an RBBP8...
...Sante et de la Recherche Medicale (INSERM) Sorbonne University Adeno-associated virus integration site 1 (AAVS1) CRISPR-associated protein 9 (Cas9) Retinoblastoma binding protein 8 (RBBP8) (CTIP)...
BioCentury | Mar 10, 2017
Targets & Mechanisms

Poly drugs for polycomb

In parallel studies, Novartis AG and Abbvie Inc. have reported inhibitors of the epigenetic regulator PRC2 that block the protein by a new mechanism, offering a complement to the inhibitors in the clinic, and more...
BioCentury | Sep 26, 2013
Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Cognitive dysfunction Retinoblastoma binding protein 4 (RBBP4; RBAP48) Studies in patient samples and mice suggest increasing RBAP48 levels could help treat...
BioCentury | Apr 22, 2010
Distillery Therapeutics

Indication: Neurology

...Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Aneurysm Cyclin M2 (CNNM2); retinoblastoma binding protein 8 (RBBP8...
...could help predict susceptibility to intracranial aneurysms. In cohorts from Europe and Japan, rs11661542, near RBBP8...
BioCentury | Apr 16, 2009
Cover Story

Probing the character of proteins

A team from The Scripps Research Institute has developed a high throughput technology that can screen compound libraries against proteins whose biochemical activities are poorly characterized. 1 The method, which relies on fluorescent activity-based chemical...
BioCentury | Dec 11, 2008
Distillery Therapeutics

This week in therapeutics

The Distillery: Therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Sjögren's syndrome Retinoblastoma binding protein 4 (RBBP4; RBAP48) A study in mice suggests that inhibiting RBAP48 may help treat or prevent...
BioCentury | May 1, 2000
Clinical News

CtIP and BRCA2 genes regulatory update

...received U.S. Patent No. 6,030,832 covering the CtIP gene and expression systems for producing the CtIP...
...to treat cancers with BRCA2 mutations. Myriad Genetics Inc. (MYGN), Salt Lake City, Utah Product: CtIP...
BioCentury | Jul 13, 1998
Tools & Techniques

Proteomics

...of their binding to a known target. In January MYGN announced the identification of MMSC1, CtIP...
BioCentury | Jan 26, 1998
Company News

Myriad Genetics other research news

...MMSC1.The CtIP gene has been linked to the BRCA1 gene in breast and ovarian cancer. CtIP...
...The mutations in BRCA1 that lead to increased risk of breast and ovarian cancer prevent CtIP...
...new pathway for cancer therapies. Myriad Genetics Inc. (MYGN), Salt Lake City, Utah Product: MMSCI, CtIP...
Items per page:
1 - 10 of 10